Biophage signs first client for phage therapy

30-Jan-2007

Biophage Pharma Inc. reported that it has concluded the sales of LISTEX(TM) to a cheese producer in the US. Securing this sale marks the beginning of a business relationship with the first client who intends to develop and use phage therapy as a biological solution to potential Listeria monocytogenes (Listeria) contamination in cheese.

On December 4, 2006, Biophage signed an MOU with EBI Food Safety (TheHague, Netherlands) for the sales and distribution of LISTEX(TM) in North America. LISTEX(TM) is the first bacteriophage product to receive FDA GRAS (Generally Recognized As Safe) recognition for the control of Listeria contaminations in cheese.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances